However, in a recent study, patients on therapy with SGLT2-inhibitors (SGLT2-I) showed decreased levels of insulin and uric acid, and lower levels of IL-6, a marker of low-grade inflammation associated to diabetes complications (52). Here, SLC5A2 is linked to diabetes mellitus.